Cybin (CYBN) News Today → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Free CYBN Stock Alerts $0.35 -0.01 (-2.78%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 6, 2024 | finance.yahoo.comCybin Provides Corporate Update and Highlights Upcoming Clinical MilestonesMay 6, 2024 | businesswire.comCybin Provides Corporate Update and Highlights Upcoming Clinical MilestonesApril 18, 2024 | businesswire.comCybin Announces Publication of Research Manuscript in the Journal of Medicinal ChemistryApril 16, 2024 | businesswire.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive DisorderApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMarch 29, 2024 | marketbeat.comCybin (OTCMKTS:CYBN) Trading Down 5.3%Cybin (OTCMKTS:CYBN) Shares Down 5.3%March 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 19, 2024 | businesswire.comCybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 MillionMarch 18, 2024 | businesswire.comCybin to Present at Public Ventures Discovery Day on March 19th in DallasMarch 15, 2024 | businesswire.comCybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety DisorderMarch 14, 2024 | markets.businessinsider.comCybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy RatingMarch 14, 2024 | msn.comCybin to begin Phase 3 study for psychedelic drug mid-yearMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA DesignationsMarch 14, 2024 | businesswire.comCybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program DesignMarch 13, 2024 | markets.businessinsider.comCybin Gets Breakthrough Therapy Designation For Its Psychedelic-based Therapeutic CYB003March 13, 2024 | businesswire.comCybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive DisorderMarch 12, 2024 | businesswire.comCybin to Host Conference Call and Webcast to Provide Program Update for CYB003March 10, 2024 | investorplace.com3 High-Potential Penny Stocks to Turn $1000 into $1 millionFebruary 27, 2024 | businesswire.comCybin to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 16, 2024 | thestreet.comCybin Inc.February 14, 2024 | finance.yahoo.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 14, 2024 | businesswire.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 13, 2024 | marketbeat.comCybin (OTCMKTS:CYBN) Trading Up 10.8%Cybin (OTCMKTS:CYBN) Stock Price Up 10.8%February 7, 2024 | finance.yahoo.comCybin Announces Grant of Two Additional Patents in Japan in Support of its DMT ProgramJanuary 23, 2024 | msn.comFDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized AnxietyJanuary 23, 2024 | msn.comCybin gets FDA clearance for Phase 2a study of psychedelic drugJanuary 23, 2024 | finance.yahoo.comCybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety DisorderJanuary 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cybin Based on Advancements in Psychedelic Treatments and Optimistic ValuationDecember 6, 2023 | finance.yahoo.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog ProgramNovember 30, 2023 | markets.businessinsider.comCybin Reports Positive Data From Phase 2 CYB003 In Major Depressive DisorderNovember 30, 2023 | finance.yahoo.comCybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg DosesNovember 20, 2023 | finance.yahoo.comCybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York CityNovember 15, 2023 | msn.comCybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 GoalsNovember 15, 2023 | benzinga.comThinking about buying stock in Tesla Inc, Chevron, Theseus Pharmaceuticals, Cybin Inc, or NXU Inc.?November 10, 2023 | benzinga.comCybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding DealNovember 10, 2023 | markets.businessinsider.comCybin Prices Offering Of About 66.67 Mln Units At $0.45/unitNovember 8, 2023 | morningstar.comCybin Inc Ordinary SharesOctober 17, 2023 | finance.yahoo.comSmall Pharma Obtains Final Order Approving ArrangementOctober 6, 2023 | benzinga.comPsyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & MoreOctober 4, 2023 | finance.yahoo.comCybin to Present at the Jefferies Inaugural Biotech CNS/Neuro SummitOctober 3, 2023 | finance.yahoo.comCybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive DisorderOctober 2, 2023 | markets.businessinsider.comCybin’s Promising Developments and Emerging Data: A Comprehensive Analysis Justifying Buy Rating and $10 Price TargetSeptember 25, 2023 | finance.yahoo.comCybin to Participate in the Cantor Global Healthcare ConferenceSeptember 20, 2023 | finanznachrichten.deWall Street Hedge Fund Genius Bets on Cybin Inc.September 20, 2023 | proactiveinvestors.comCybin shares continue to rise on major investment from Steve Cohen's hedge fundSeptember 5, 2023 | benzinga.comCybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMTSeptember 5, 2023 | finance.yahoo.comCybin Announces Grant of U.S. Patent Covering Deuterated TryptaminesSeptember 1, 2023 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About CybinAugust 29, 2023 | marketwatch.comCybin Buying Small Pharma in All-Stock Transaction Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street Legend Warns: "A Strange Day Is Coming to America" (Ad)Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more. CYBN Media Mentions By Week CYBN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYBN News Sentiment▼0.000.91▲Average Medical News Sentiment CYBN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYBN Articles This Week▼01▲CYBN Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ProQR Therapeutics News Today Acrivon Therapeutics News Today BeyondSpring News Today NervGen Pharma News Today vTv Therapeutics News Today Assembly Biosciences News Today MAIA Biotechnology News Today AVROBIO News Today Brainstorm Cell Therapeutics News Today Immutep News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYBN) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for AIWeiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
